| abstract |
This invention is related to novel prolinamide derivatives and analogues of general formula (I) wherein Q is C3-C8 alkyl, or C1-C8 alkyl substituted by phenoxy or saturated or unsaturated 5 to 7 membered ring optionally containing one or more heteroatoms chosen independently from nitrogen, oxygen or sulphur, the rings being optionally substituted by one or more halogen atoms, trifluoromethyl, C1-C6 alkyl, hydroxyl, C1-C6 alkoxy; X is an oxygen, sulphur or a NR5 group; R, R1 are independently hydrogen, C1-C6 alkyl, halogen, trifluoromethyl, hydroxy or C1-C6 alkoxy; R2 is hydrogen or hydroxyl; R3 R4 R5 are independently hydrogen or straight or branched C1-C3 alkyl; n is an integer from 1 to 3 and a pharmaceutically acceptable salt or prodrug thereof, that areactive as sodium and/or calcium channel modulators and/or as selective MAOB inhibitors and therefore useful in preventing, alleviating and curing a wide range of pathologies, including, but not limited to, neurological, psychiatric, cardiovascular, inflammatory, ophthalmic, urologic, metabolic and gastrointestinal diseases, where the above mechanisms have been described as playing a pathological role. |